Based on the AN2 Therapeutics Inc stock forecast from 2 analysts, the average analyst target price for AN2 Therapeutics Inc is USD 14.33 over the next 12 months. AN2 Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of AN2 Therapeutics Inc is Slightly Bearish, which is based on 2 positive signals and 3 negative signals. At the last closing, AN2 Therapeutics Inc’s stock price was USD 2.40. AN2 Therapeutics Inc’s stock price has changed by -3.23% over the past week, -27.93% over the past month and -71.80% over the last year.
No recent analyst target price found for AN2 Therapeutics Inc
No recent average analyst rating found for AN2 Therapeutics Inc
Company Overview AN2 Therapeutics Inc
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, which is in a pivotal Phase 2/3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease. The company also develops AN2-502998 (AN15368), an investigational, boron-based small molecule in development for the treatment of chronic Chagas disease that is in preclinical trials. It has a license agreement with Anacor Pharmaceuticals, Inc. to use, develop, manufacture, commercialize, or otherwise exploit certain compounds and products, including epetraborole, for the treatment, diagnosis, or prevention of all human diseases; and Brii Biosciences Limited to research, develop, manufacture, and commercialize certain compounds and products, including epetraborole, in China, Hong Kong, Taiwan, and Macau for the diagnosis, treatment, and prevention of human diseases. The company was incorporated in 2017 and is headquartered in Menlo Park, California. Address: 1800 El Camino Real, Menlo Park, CA, United States, 94027 Read Less
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, which is in a pivotal Phase 2/3 clinical trial as a once-daily oral treatment for patients with ...Read More
Frequently Asked Questions About AN2 Therapeutics Inc (ANTX) Stock
Based on ratings from 2 analysts AN2 Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 2 buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on ANTX's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for ANTX is USD 14.33 over the next 12 months. The maximum analyst target price is USD 30 while the minimum anlayst target price is USD 6.
ANTX stock's Price/Earning ratio is 3.96.
Our analysis grades ANTX stock's Price / Earning ratio at F. This means that ANTX stock's Price/Earning ratio is above 43.00000000000001% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this ANTX may be fairly valued for its sector
The last closing price of ANTX's stock was USD 2.40.
The most recent market capitalization for ANTX is USD 0.07B.
Based on targets from 2 analysts, the average taret price for ANTX is projected at USD 14.33 over the next 12 months.
This means that ANTX's stock price may go up by +497.22% over the next 12 months.
We can't find any ETFs which contains AN2 Therapeutics Inc's stock.
As per our most recent records AN2 Therapeutics Inc has 41 Employees.
AN2 Therapeutics Inc's registered address is 1800 El Camino Real, Menlo Park, CA, United States, 94027.
You can get more information about it from AN2 Therapeutics Inc's website at https://www.an2therapeutics.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
What not to like
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ANTX !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
